Investigational drug · Phase 2
IN-207907
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Sarcopenia in Elderly.
Phase 2Last checked: Nov 20, 2026Latest source record: Jun 25, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "IN-207907"
First trial start
2026
Sep 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "IN-207907", any sponsor or status.
Conditions studied
As listed on its trial records.
- Sarcopenia in Elderly
Largest trials
Live from ClinicalTrials.gov: studies naming "IN-207907" as an intervention, largest first.
- A Study to Evaluate the Efficacy and Safety of IN-207907 Injection in Elderly Patients With SarcopeniaPivotal-lookingNot yet recruiting
HK inno.N CorporationIndustry
NCT07668180 · 100 participants (planned) · Start Sep 2026 · Primary completion Feb 2028
Drug: IN-207907 120 mg; IN-207907 240 mg and 2 more · For: Sarcopenia in Elderly
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Sarcopenia in Elderly
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.